[1]王 甲,刘荣梅,杨肖沫,等.基于倾向指数匹配法的ARB类两种降压药物的成本-效果分析[J].医学信息,2023,36(16):84-88.[doi:10.3969/j.issn.1006-1959.2023.16.015]
　WANG Jia,LIU Rong-mei,YANG Xiao-mo,et al.Cost-effectiveness Analysis of Two Kinds of ARB Antihypertensive Drugs Based on Propensity Score Matching Method[J].Journal of Medical Information,2023,36(16):84-88.[doi:10.3969/j.issn.1006-1959.2023.16.015]
点击复制

基于倾向指数匹配法的ARB类两种降压药物的成本-效果分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年16期
页码:
84-88
栏目:
论著
出版日期:
2023-08-15

文章信息/Info

Title:
Cost-effectiveness Analysis of Two Kinds of ARB Antihypertensive Drugs Based on Propensity Score Matching Method
文章编号:
1006-1959（2023）16-0084-05
作者:
王 甲; 刘荣梅; 杨肖沫; 等
（河南省人民医院心脏中心/阜外华中心血管病医院/郑州大学华中阜外医院/河南省慢病健康管理重点实验室河南省基层高血压管理指导中心1，药学部2，河南 郑州 451450）
Author(s):
WANG Jia; LIU Rong-mei; YANG Xiao-mo; et al.
(Henan Province Grassroots Hypertension Management Guidance Center1,Department of Pharmacy2,Heart Center of Henan Provincial People’s Hospital/Central China Fuwai Hospital/Central China Fuwai Hospital of Zhengzhou University/Henan Key Laboratory for Health Management of Chronic Diseases,Zhengzhou 451450,Henan,China)
关键词:
厄贝沙坦; 阿利沙坦酯; 血管紧张素Ⅱ受体拮抗剂; 成本-效果
Keywords:
Alisartan isoproxil; Irbesartan; Angiotensin Ⅱ receptor antagonists; Cost-effectiveness
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2023.16.015
文献标志码:
A
摘要:
目的 基于倾向指数匹配法评价血管紧张素受体拮抗剂（ARB）类降压药物厄贝沙坦与阿利沙坦酯两种降压药物的成本-效果。方法 选取2018年1月-2021年6月河南省某三甲心血管病医院服用厄贝沙坦与阿利沙坦酯的门诊高血压患者，以患者治疗方案为因变量，以协变量（所有影响抗高血压药物治疗效果的变量）为自变量建立Logistic回归模型，计算高血压患者的倾向指数，以倾向指数为距离函数进行样本卡钳匹配，利用匹配后的样本进行成本-效果分析。结果 匹配后协变量在服用厄贝沙坦组和服用阿利沙坦酯组两组之间的分布达到很好的均衡；在收缩压和舒张压下降率上，阿利沙坦酯片（信立坦）（308.66、657.21）的成本-效果较厄贝沙坦片（安博维）（135.71、101.54）升高2.5倍左右。结论 与阿利沙坦酯比较，厄贝沙坦的成本-效果更好。
Abstract:
Objective To evaluate the cost-effectiveness of two kinds of angiotensin receptor blockers irbesartan and allisartan isoproxil based on propensity score matching method.Methods From January 2018 to June 2021, outpatients with hypertension who took irbesartan and allisartan isoproxil in a tertiary cardiovascular hospital in Henan Province were selected. The patient’s treatment plan was used as the dependent variable, and the covariate (all variables affecting the therapeutic effect of antihypertensive drugs) was used as the independent variable to establish a Logistic regression model. The propensity index of hypertensive patients was calculated, and the propensity index was used as the distance function to match the sample caliper. The matched samples were used for cost-effectiveness analysis.Results After matching, the distribution of covariates between the irbesartan group and the allisartan isoproxil group reached a good equilibrium. In terms of systolic and diastolic blood pressure reduction rates, the cost-effectiveness of allisartan isoproxil tablets (308.66, 657.21) was about 2.5 times higher than that of irbesartan tablets (135.71, 101.54).Conclusion Compared with allisartan isoproxil, the cost-effectiveness of irbesartan is better.

参考文献/References:

[1]Zhou M,Wang H,Zeng X,et al.Mortality,morbidity,and risk factors in China and its provinces,1900-2017:a systematic for the Global Burden of Disease Study 2017[J].Lancet,2019,394(10204):1145-1158.[2]中国高血压防治指南修订委员会,高血压联盟（中国）,中华医学会心血管病学分会,等.中国高血压防治指南（2018 年修订版）[J].中国心血管杂志,2019,24(1):24-56.[3]张毓辉,柴培培,翟铁民,等.2011年我国心脑血管疾病治疗费用核算与分析[J].中国循环杂志,2020,35(9):859-864. [4]汪月南.国产ARB类降压药物在轻中度高血压患者中的应用效果研究[J].河北医学,2016,22(4):659-661. [5]段承阿鑫,隋宾艳,艾丹丹,等.阿利沙坦酯治疗原发性高血压的临床综合评价[J].中国合理用药探索,2022,19(3):46-55.[6]谢立强,胡信群.阿利沙坦酯片与厄贝沙坦片治疗高血压合并冠心病患者的临床研究[J].中国临床药理学杂志,2021,37(19):2562-2568.[7]国家心血管病中心国家基本公共卫生服务项目基层高血压管理办公室,国家基层高血压管理专家委员会.国家基层高血压防治管理指南2020版[J].中国循环杂志,2021,36(3):209-220.[8]Austin PC.The performance of different propensity-score methods for estimating differences in proportions(risk differences or absolute risk reductions)in observational studies[J].Stat Med,2010,29(20):2137-2148．[9]郭申阳,马克·W.弗雷泽译.倾向值分析:统计方法与应用[M].重庆:重庆大学出版社,2012:26-27.[10]焦明旭,张晓,刘迪,等.倾向性评分匹配在非随机对照研究中的应用[J].中国卫生统计,2016,33(2):350-352. [11]周洁,张晟,何书,等.使用R和 Stata 软件实现倾向性评分匹配[J].中国卫生统计,2018,35(4):628-632.[12]黎国威,张玲,陈裕明,等.倾向性评分方法在观察性研究中的应用[J].中国循证医学杂志,2021,21(4):469-474.[13]冯芮华,王晓万,王增武,等.基于倾向指数匹配法的两种社区常用二联降压药物组合的成本－效果分析[J].中国全科医学,2017,20(36):4523-4528.[14]王鸿懿,霍勇,孙宁玲,等.阿利沙坦酯联合利尿剂或钙通道阻滞剂对单药治疗未达标高血压患者的疗效及安全性[J].中华高血压杂志,2021,29(5):420-427.[15]庞琦.阿利沙坦酯治疗老年高血压的临床疗效及其对患者血管内皮功能的影响[J].高血压合理用药杂志,2022,15(6):44-46.[16]林春兰,蔡娅娟.阿利沙坦酯与氯沙坦钾治疗高血压的有效性及安全性比较[J].临床合理用药,2021,14(5):37-38.[17]汤瑜昳,杨德辉,易定锋.阿利沙坦酯和缬沙坦治疗高血压病合并高尿酸血症效果比较[J].湖南师范大学学报（医学版）,2020,17(1):40-42.[18]张丽丽,宋沧桑,张阳,等. ARB 类药物治疗原发性高血压的药物经济学研究[J].中国药物评价,2021,38(1):74-77.[19]朱立新,魏巍.不同用药方案治疗原发性高血压的疗效分析[J].慢性病学杂志,2020,21(1):65-67.[20]吴艳婷.坎地沙坦与阿利沙坦酯在原发性高血压患者治疗中的应用效果比较[J].哈尔滨医药,2020,40(1):9-10.

相似文献/References:

[1]张 挺.厄贝沙坦联合美托洛尔治疗慢性充血性心衰的疗效观察[J].医学信息,2018,31(05):125.[doi:10.3969/j.issn.1006-1959.2018.05.044]
　ZHANG Ting.Efficacy of Irbesartan Combined with Metoprolol in the Treatment of Chronic Congestive Heart Failure[J].Journal of Medical Information,2018,31(16):125.[doi:10.3969/j.issn.1006-1959.2018.05.044]
[2]孙洪艳.硝苯地平联合厄贝沙坦治疗糖尿病合并高血压的疗效观察[J].医学信息,2018,31(10):131.[doi:10.3969/j.issn.1006-1959.2018.10.043]
　SUN Hong-yan.Efficacy of Nifedipine Combined with Irbesartan in the Treatment of Diabetes Complicated with Hypertension[J].Journal of Medical Information,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.10.043]
[3]鲍江波.肾炎康复片联合厄贝沙坦治疗慢性肾炎蛋白尿的临床效果[J].医学信息,2020,33(13):162.[doi:10.3969/j.issn.1006-1959.2020.13.050]
　BAO Jiang-bo.Clinical Effect of Nephritis Rehabilitation Tablets Combined with Irbesartan on Proteinuria of Chronic Nephritis[J].Journal of Medical Information,2020,33(16):162.[doi:10.3969/j.issn.1006-1959.2020.13.050]
[4]杨启明,魏先森.诺欣妥、倍他乐克联合拜新同治疗老年高血压合并慢性心功能不全的临床研究[J].医学信息,2024,37(07):115.[doi:10.3969/j.issn.1006-1959.2024.07.022]
　YANG Qi-ming,WEI Xian-sen.A Clinical Study on the Treatment of Senile Hypertension Complicated with Chronic Cardiac Insufficiency by Ningroxinto, Betaloc Combined with Nifedipine[J].Journal of Medical Information,2024,37(16):115.[doi:10.3969/j.issn.1006-1959.2024.07.022]

更新日期/Last Update: 1900-01-01